A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis - Innovaderm Research

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Test

Post navigation

FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Dermatology Clinic
3530 Saint-Laurent boulevard
Suite 400
Montreal, QC, H2X 2V1, Canada

© Innovaderm 2025. All rights reserved.